On Mar. 29, 2021, Humanigen announced positive topline results from its Phase 3 clinical trial evaluating the efficacy…
On Mar. 24, 2021, Clover Biopharmaceuticals and Dynavax Technologies announced the first participants have were dosed in Clover’s…
On Mar. 22, 2021, CureVac announced plans to expand and further specify the protocols of its ongoing late-stage…
On Mar. 22, 2021, the NIH announced that results from a large clinical trial in the U.S. and…
On Mar. 11, 2021, Rigel Pharma announced the completion of patient enrollment in a multi-center Phase 2 clinical…
On Mar. 8, 2021, the NIH announced that it had launched the last of three phase 3 clinical…
On Mar. 8, 2021, AXIM Biotechnologies announced that it had successfully completed point-of-care clinical trials on its much…
On Mar. 5, 2021, Abivax announced tthat it was halting the miR-AGE phase 2b/3 clinical trial in high-risk…
On Mar. 5, 2021, Innovation Pharmaceuticals reported that eight sites were participating in the Company’s international Phase 2…
On Mar. 4, 2021, the NIH announced that the ACTIV-3 clinical trial evaluating the safety and efficacy of…
On Mar. 2, 2021, the NIH halted a clinical trial evaluating the safety and effectiveness of COVID-19 convalescent…
On Mar. 2, 2021, Innovation Pharmaceuticals reported that eight sites were participating in the Companyï¾’s international Phase 2…
On Feb. 26, 2021, Innovation Pharmaceuticals announced that after an interim review, by an independent Data Monitoring Committee…
On Feb. 26, 2021, Novavax and Takeda Pharmaceutical announced an exclusive license agreement for Takedaï¾’s development, manufacturing and…
On Feb. 25, 2021, Altimmune announced that it had commenced enrollment in a Phase 1 clinical trial of…
On Feb. 24, 2021, NeuroRx, announced that the phase 2b/3 trial of ZYESAMI for the treatment of Respiratory…
On Feb. 23, 2021, the NIH announced that a randomized, placebo-controlled Phase 1 clinical trial of two monoclonal…
On Feb. 22, 2021, Novavax and the complete enrollment of PREVENT-19, its pivotal Phase 3 study in the…
On Feb. 19, 2021, Johnson & Johnson announced that Janssen-Cilag had submitted for Emergency Use Listing (EUL) to…
On Feb. 18, 2021, scientists at the University of Oxford announced that the Randomised Evaluation of COVID-19 Therapy…
On Feb. 18, 2021, Novavax and announced a Memorandum of Understanding (MOU) with Gavi, the Vaccine Alliance, to…
On Feb. 18, 2021, Washington University pediatric infectious diseases doctors announced plans to launch clinical trials in the…
On Feb. 17, 2021, Altimmune announced that the FDA had cleared the Companyï¾’s Investigational New Drug (IND) application…
On Feb. 16, 2021, Anixa Biosciences announced that animal testing had commenced with two proprietary compounds that have…
On Feb. 16, 2021, Johnson & Johnson announced that subsidiary Janssen Biotech, has submitted a conditional Marketing Authorisation…
On Feb. 15, 2021, Novavax and SK Bioscience announced an expanded collaboration and license agreement. In addition to…
On Feb. 11, 2021, the the Military Health System (MHS) announced partcipation in the AstraZeneca phase III clinical…
On Feb. 8, 2021, the NIH announced that an international randomized, controlled Phase 3 clinical trial had begun…
On Feb. 8, 2021, NanoViricides announced that its broad-spectrum anti-coronavirus drug candidate for the treatment of COVID-19 infections…
On Feb. 4, 2021, Corvus Pharmaceuticals announced that it had initiated a Phase 3 clinical trial of CPI-006…